Targacept (Nasdaq: TRGT) is turning to the public markets to raise cash for drug development.
The Winston-Salem based biopharmaceutical firm which focuses on nervous system disorders said earlier this week it plans to raise $75 million through a stock offering.
Targacept shares traded at $20.77 in late Wednesday morning trading.
Drug giant GlaxoSmithKline (NYSE: GSK) and Targacept disclosed plans to end a partnership in March after GSK changed its focus for future drug development. GSK had invested $45 million in the partnership, including a $15 million investment in the company. (Read details here.)
The stock offering will be managed by Deutsche Bank Securities.
Get the latest news alerts: Follow WRAL Tech Wire at Twitter.